First-line treatment with TREMFYA® shows significant inhibition of radiographic progression at Week 24, which was sustained through Week 48, preserving joint health with a well-established safety ...

According to a systematic review and meta-analyses of observational and clinical studies, approximately 25% of individuals with psoriasis develop psoriatic arthritis (PsA). Persistent articular ...

Johnson & Johnson (J&J) has announced new data showing that Tremfya (guselkumab) reduces symptoms of psoriatic arthritis (PsA) and also inhibits structural joint damage associated with the condition.

The human skeletal system evolved to support a specific weight range, with joints designed to absorb and distribute forces from daily movement. When body weight exceeds these natural parameters, the ...

That satisfying pull you feel during a deep stretch might not be the beneficial sensation you think it is. While stretching is often portrayed as universally beneficial and risk-free, the reality is ...

A harmless form of knee clicking, medically known as crepitus, occurs due to tiny air bubbles trapped in the joint fluid. These bubbles release during movement, producing a popping or clicking sound ...

Additionally, for patients in the study's placebo group, who switched to TREMFYA ® at Week 24, the rate of radiographic progression from baseline to Week 24 (0.96) was reduced by 57% (to 0.41) from ...